Filing Flows

Filing Flows › 8-K events › Corcept Therapeutics

Corcept Therapeutics: results of operations

Form 8-K filed Nov 3, 2026 · items 2.02, 7.01

FDA decisionsCorcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

What the filing says

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update • Revenue of $340.5 million, a 64 percent increase over the same period in 2025

ScaleThe filing names $340.5M: about 25% of Corcept Therapeutics' annual revenue ($1.36B, four times the latest quarter).

Read the filing on SEC EDGAR →

What usually followsAcross 69,115 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Every item ranked →

Corcept Therapeutics at a glance

Latest quarterQ3 2026
Revenue$340.5M
Revenue Y/Y+64%
Operating margin33.7%
IndustryPharmaceutical Preparations

Corcept Therapeutics, Q3 2026: revenue $340M (+64% year over year), operating margin 33.7%. The chart follows the revenue to costs, profit and cash.

Corcept Therapeutics: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.